Chitosan-conjugated TLR7/8 agonist improves response against carbohydrate antigens in cancer vaccines, suggesting enhanced immunogenicity.
The TLR7/8 agonist imidazoquinoline (IMDQ), 1-(4-(amino-methyl)benzyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-4-amine, conjugated to chitosan was found to be a superior adjuvant to aluminum salts for vaccination against tumor-associated carbohydrate antigens.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: